Quality of life study in patients with unresectable locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel versus gemcitabine alone:ax-panc-sy001: A phase II randomized study.

被引：2

作者：

Yalcin, Suayib

Dane, Faysal

Oksuzoglu, Berna

Yildirim, Nuriye

Isikdogan, Abdurrahman

Ozkan, Metin

Demirag, Guzin

Coskun, Hasan Senol

Karabulut, Bulent

Evrensel, Turkkan

Ustaoglu, Mehmet Ali

Ozdemir, Feyyaz

Turna, Hande

Yavuzsen, Tugba

Aykan, Faruk

Sevinc, Alper

Akbulut, Hakan

Yuce, Deniz

Hayran, Mutlu

Kilickap, Saadettin

机构：

[1] Hacettepe Univ, Ankara, Turkey

[2] Marmara Univ, Istanbul, Turkey

[3] Dr A Y Ankara Oncol Training & Res Hosp, Ankara, Turkey

[4] Ankara Numune Training & Res Hosp, Ankara, Turkey

[5] Dicle Univ, Med Sch, Diyarbakir, Turkey

[6] Erciyes Univ, Kayseri, Turkey

[7] Ondokuzmayis Univ Med Oncol, Samsun, Turkey

[8] Akdeniz Univ, Antalya, Turkey

[9] Ege Univ, Izmir, Turkey

[10] Uludag Univ, Pittsburgh, PA USA

[11] Lutfi Kirdar Hosp, Istanbul, Turkey

[12] Karadeniz Tech Univ, Fac Med, Trabzon, Turkey

[13] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey

[14] Dokuz Eylul Univ, Oncol Inst, Izmir, Turkey

[15] Istanbul Univ, Inst Oncol, Istanbul, Turkey

[16] Gaziantep Univ, Gaziantep, Turkey

[17] Hacettepe Univ, Canc Inst, Ankara, Turkey

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期

关键词：

D O I：

10.1200/JCO.2018.36.4_suppl.346

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

346

引用

页数：1

共 50 条

[31] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.
Feliu Batlle, Jaime
Jorge Fernandez, Monica
Macarulla, Teresa
Massuti, Bartomeu
Albero, Ana
Gonzalez, Federico
Quintero Aldana, Guillermo Alfonso
Delgado Mingorance, J. Ignacio
Fernandez Montes, Ana
Garcia Piernavieja, Carmen
Valladares-Ayerbes, Manuel
Garcia Giron, Carlos
Mondejar, Rebeca
Vicente, Pilar
Casado, Esther
Gonzalez Cebrian, Irene
Lopez-Vivanco, Guillermo
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[32] Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.
Pijnappel, Esther N.
Wassenaar, Nienke P. M.
Gurney-Champion, Oliver J.
Klaassen, Remy
van der Lee, Koen S.
Pleunis-van Empel, Marjolein
Richel, Dick J.
Legdeur, Marie-Cecile J. C.
Nederveen, Aart J.
Van Laarhoven, Hanneke W. M.
Wilmink, Johanna
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[33] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Weiss, Glen J.
Blaydorn, Lisa
Beck, Julia
Bornemann-Kolatzki, Kirsten
Urnovitz, Howard
Schutz, Ekkhard
Khemka, Vivek
INVESTIGATIONAL NEW DRUGS, 2018, 36 (01) : 96 - 102
[34] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
Fukahori, Masaru
Miwa, Keisuke
Murotani, Kenta
Naito, Yoshiki
Ushijima, Tomoyuki
Sakaue, Takahiko
Tanaka, Toshimitsu
Nagasu, Sachiko
Suga, Hideya
Kakuma, Tatsuyuki
Okabe, Yoshinobu
Torimura, Takuji
MEDICINE, 2021, 100 (20) : E26052
[35] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss
Lisa Blaydorn
Julia Beck
Kirsten Bornemann-Kolatzki
Howard Urnovitz
Ekkhard Schütz
Vivek Khemka
Investigational New Drugs, 2018, 36 : 96 - 102
[36] Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer
Perez, Kimberly
Chiarella, Anna M.
Cleary, James M.
Horick, Nora
Weekes, Colin
Abrams, Thomas
Blaszkowsky, Lawrence
Enzinger, Peter
Giannakis, Marios
Goyal, Lipika
Meyerhardt, Jeffrey A.
Rubinson, Douglas
Yurgelun, Matthew B.
Goessling, Wolfram
Giantonio, Bruce J.
Brais, Lauren
Germon, Victoria
Stonely, Danielle
Raghavan, Srivatsan
Bakir, Basil
Das, Koushik
Pitarresi, Jason R.
Aguirre, Andrew J.
Needle, Michael
Rustgi, Anil K.
Wolpin, Brian M.
ONCOLOGIST, 2023, 28 (05): : 425 - 432
[37] Phase Ib/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
Acoba, Jared David
Rock, Amy
Wong, Hing C.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[38] Phase I study of chemoradiation therapy (nab-paclitaxel/Gemcitabine) in 15 patients with unresectable locally advanced pancreatic cancer (UR-LAPC).
Sueyoshi, Hironari
Ioka, Tatsuya
Tamura, Takeshi
Takada, Ryoji
Fukutake, Nobuyasu
Ashida, Reiko
Ohkawa, Kazuyoshi
Takahashi, Hidenori
Teshima, Teruki
Katayama, Kazuhiro
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[39] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
Kamata, Ken
Imai, Hajime
Matsumoto, Hisakazu
Yamashita, Yukitaka
Kato, Takao
Nishi, Katsuhisa
Omoto, Shunsuke
Minaga, Kosuke
Yamao, Kentaro
Hyodo, Tomoko
Im, Sung-Woon
Hara, Akane
Yoshikawa, Tomoe
Ishikawa, Rei
Okamoto, Ayana
Yamazaki, Tomohiro
Nakai, Atsushi
Ueshima, Kazuomi
Chiba, Yasutaka
Takenaka, Mamoru
Watanabe, Tomohiro
Kitano, Masayuki
Kudo, Masatoshi
JGH OPEN, 2023, 7 (09): : 659 - 666
[40] Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer
Tabernero, Josep
Chiorean, E. Gabriela
Infante, Jeffrey R.
Hingorani, Sunil R.
Ganju, Vinod
Weekes, Colin
Scheithauer, Werner
Ramanathan, Ramesh K.
Goldstein, David
Penenberg, Darryl N.
Romano, Alfredo
Ferrara, Stefano
Von Hoff, Daniel D.
ONCOLOGIST, 2015, 20 (02): : 143 - 150

← 1 2 3 4 5 →